cr for a company with essentially no debt, page-3

A well considered post Madarch. I was hoping that the extra funds needed for all of the company's prospects could come from options being exercised, existing sales and bank debt although obviously not. Still, this extra $10 million means the company can dramatically ramp up manufacturing of Cardiocel and marketing and launch across the EU and US. Also the progression of the vaccine trials, no small thing. I think Cardiocel alone will ultimately justify a share price of between 25-30c a year from now although time as always will tell. Cheers.